Search results
Results from the WOW.Com Content Network
The first list was published in 1977 and included 208 medications. [8] [2] [9] The WHO updates the list every two years. [10] There are 306 medications in the 14th list in 2005, [11] 410 in the 19th list in 2015, [10] 433 in the 20th list in 2017, [12] [13] 460 in the 21st list in 2019, [14] [15] [16] and 479 in the 22nd list in 2021.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
COVID-19. Pfizer. 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine. HIV. non- nucleoside reverse transcriptase inhibitor. Nitazoxanide. Broad-spectrum antiviral.
August 8, 2024 at 10:55 AM. By Mariam Sunny. (Reuters) -The U.S. Food and Drug Administration has approved Citius Pharmaceuticals' therapy for patients with a form of blood cancer who have ...
Noor Hisham bin Abdullah (born Yew Ming Seong; 21 April 1963) was a Malaysian civil servant as well as breast and endocrine surgeon. He was the Director-General of Health and President of Malaysia Medical Council [1] from March 2013 to his retirement in April 2023. Prior to the appointment, he served as the Deputy Director General of Health ...
Psychiatric medication. A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric ...
The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use of the drug or other substance under medical supervision. The complete list of Schedule I substances is as follows. [1]
Four S1P modulators: Fingolimod (Gilenya), an oral treatment and the first oral therapy approved for multiple sclerosis. Siponimod (Mayzent), oral. Approved in March 2019 for CIS, RRMS and SPMS [11][12] Ozanimod: oral. It was approved by the FDA in March 2020 with the trade name Zeposia [13][14][15] Ponesimod (Ponvory)